Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03066661

Expanded Access Status : No longer available

First Posted : February 28, 2017

Last Update Posted : April 26, 2019

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Hoffmann-La Roche

Tracking Information
First Submitted Date	February 23, 2017
First Posted Date	February 28, 2017
Last Update Posted Date	April 26, 2019

Descriptive Information
Brief Title	Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Brief Summary	Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.
Detailed Description	Not Provided
Study Type	Expanded Access
Intervention	Drug: Entrectinib Open-label expanded access, capsules Other Name: RXDX-101
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Expanded Access Status	No longer available
Contacts	Contact information is only displayed when the study is recruiting subjects
Listed Location Countries	United States
Removed Location Countries

Administrative Information
NCT Number	NCT03066661
Current Responsible Party	Hoffmann-La Roche
Original Responsible Party	Same as current
Current Study Sponsor	Hoffmann-La Roche
Original Study Sponsor	Same as current
Collaborators	Not Provided
Investigators	Not Provided
PRS Account	Hoffmann-La Roche
Verification Date	April 2019

To Top